Riot Platforms Inc vs Sana Biotechnology Inc — how do they compare? Riot Platforms Inc trades at $21.93 (market cap $8.35B), while Sana Biotechnology Inc trades at $3.24 (market cap $1.03B). The key difference: Riot Platforms Inc is far larger — about 8.1× Sana Biotechnology Inc's market cap, and Riot Platforms Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| RIOT | SANA | |
|---|---|---|
Market Cap | $8.35B | $1.03B |
Sector | Technology | Health |
52-Week High | $28.67 | $5.92 |
52-Week Low | $11.83 | $2.68 |
Enterprise Value | $8.76B | $946.04M |
Signals from Pluang's Aura AI — not financial advice
RIOT Platforms trades at $22.26, up 2.11% today, with a bullish technical signal from moving averages. The stock shows strong analyst support with 94.7% buy ratings and a $33 consensus price target. Recent news highlights a transformative $9.1 billion AI data center deal with Anthropic, shifting focus from Bitcoin mining to high-margin AI infrastructure. However, fundamental challenges persist with negative net income margins and consecutive earnings misses.
The outlook balances significant AI-driven growth potential against current profitability concerns. The Anthropic partnership provides long-term revenue visibility but execution risks remain. With the stock trading near analyst price targets, upside depends on successful AI transition and improved financial performance. Key risks include competitive pressures, regulatory uncertainty, and continued cash flow challenges.
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Trailing returns across standard periods
Latest headlines on both assets
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →